Catinazzo Thomas 4

What Happened

• Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares on July 6, 2026. The weighted-average sale price reported was $18.69 per share, for total gross proceeds of approximately $331,131. This was a sale (not a purchase), and the transaction was reported as an open-market/private sale.

Key Details

• Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely filing).
• Price range: trades executed at prices between $18.39 and $19.38; $18.69 is the weighted-average sale price (reporting person can provide per-trade breakdown on request).
• Shares disposed: 17,717 (all reported as sales).
• Shares owned after transaction: not specified in the excerpt provided; the filing notes include 9,807 shares underlying restricted stock units.
• Notable footnotes: transaction executed under a Rule 10b5-1 trading plan adopted October 30, 2025 (preplanned trades).

Context

• Sales under a 10b5-1 plan are typically prearranged and do not necessarily indicate a change in the insider’s view of the company. This was a routine insider sale rather than an acquisition or option exercise.